Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 3 trial of abetimus sodium in systemic lupus erythematosus with renal involvement
2006-000674-73Phase 3Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Jun 2006
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abetimus sodium in systemic lupus erythematosus (SLE) (3 arms), sponsored by La Jolla Pharmaceutical Company. Primary endpoint: Time to first renal flare. Started Jun 2006; status: completed.
02
Drugs
abetimus sodium
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2006-000674-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000674-73.